Personal stories
From patient to researcher: Justin Moy’s fight against LAMA2-CMD
This is a summarized version of an original article published by Boston University. Read the full article here. For Justin…
News
-
![]()
Personal stories
-
![]()
News
Markus Rüegg’s mission: Developing a gene therapy for LAMA2-CMD
This article is a translated and summarized version of an original German interview with Professor Markus Rüegg Hope for a…
-
![]()
News
A look back on a conference to shape LAMA2 clinical care guidelines
We are delighted to reflect on the success of the ENMC conference, initiated by Voor Sara and Cure CMD. Together,…
-
![]()
News
Help shape the future of LAMA2-Related Dystrophy care guidelines
In January 2025, clinicians specialising in LAMA2-Congenital Muscular Dystrophy (LAMA2-CMD) will convene in The Netherlands to begin developing updated care…
-
![]()
News
Modalis Therapeutics receives FDA Orphan Drug designation
Modalis Therapeutics has been granted U.S. FDA’s grant of Orphan Drug Designation (ODD) for MDL-101, a cutting-edge treatment for congenital…
-
![]()
Research updates
Spain’s ongoing LAMA2-CMD natural history study
In 2022, a natural history study was initiated with LAMA2-CMD patients at Barcelona’s Vall d’Hebron Institute of Research. Natural history…
The driving forces behind Lama2.com
Bekijk alle partners
